Fang Y, Li W, Dong C, Gao B, Guo W, Li M
Redox Rep. 2024; 29(1):2428147.
PMID: 39607819
PMC: 11610352.
DOI: 10.1080/13510002.2024.2428147.
Zhao Y, Yang M, Liang X
J Transl Med. 2024; 22(1):1057.
PMID: 39587666
PMC: 11587765.
DOI: 10.1186/s12967-024-05740-4.
von Brackel F, Oheim R
JBMR Plus. 2024; 8(8):ziae064.
PMID: 38957399
PMC: 11215550.
DOI: 10.1093/jbmrpl/ziae064.
Koide R, Shigemasa R, Hashimoto K, Tatsumi Y, Hayashi H, Suzuki T
In Vivo. 2023; 38(1):114-121.
PMID: 38148091
PMC: 10756453.
DOI: 10.21873/invivo.13417.
Xu L, Zhang M, Pan J, Xu X, Zhang Y, Han X
Front Pharmacol. 2023; 14:1135366.
PMID: 37007035
PMC: 10063813.
DOI: 10.3389/fphar.2023.1135366.
Fighting age-related orthopedic diseases: focusing on ferroptosis.
Ru Q, Li Y, Xie W, Ding Y, Chen L, Xu G
Bone Res. 2023; 11(1):12.
PMID: 36854703
PMC: 9975200.
DOI: 10.1038/s41413-023-00247-y.
Cdh5-mediated Fpn1 deletion exerts neuroprotective effects during the acute phase and inhibitory effects during the recovery phase of ischemic stroke.
Zheng H, Guo X, Kang S, Li Z, Tian T, Li J
Cell Death Dis. 2023; 14(2):161.
PMID: 36841833
PMC: 9968354.
DOI: 10.1038/s41419-023-05688-1.
Associated Effect of and Polymorphisms on Iron Overload.
Duca L, Granata F, Pierro E, Brancaleoni V, Graziadei G, Nava I
Metabolites. 2022; 12(10).
PMID: 36295822
PMC: 9612384.
DOI: 10.3390/metabo12100919.
A small molecule redistributes iron in ferroportin-deficient mice and patient-derived primary macrophages.
Ekaputri S, Choi E, Sabelli M, Aring L, Green K, Chang J
Proc Natl Acad Sci U S A. 2022; 119(26):e2121400119.
PMID: 35737834
PMC: 9245668.
DOI: 10.1073/pnas.2121400119.
Assessment of iron overload in a cohort of Sri Lankan patients with transfusion dependent beta thalassaemia and its correlation with pathogenic variants in HBB, HFE, SLC40A1, and TFR2 genes.
Dissanayake R, Samarasinghe N, Waidyanatha S, Pathirana S, Neththikumara N, Dissanayake V
BMC Pediatr. 2022; 22(1):344.
PMID: 35705926
PMC: 9199146.
DOI: 10.1186/s12887-022-03191-8.
Hemochromatosis classification: update and recommendations by the BIOIRON Society.
Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler M, Porto G
Blood. 2021; 139(20):3018-3029.
PMID: 34601591
PMC: 11022970.
DOI: 10.1182/blood.2021011338.
Appropriate Clinical Genetic Testing of Hemochromatosis Type 2-4, Including Ferroportin Disease.
Kowdley D, Kowdley K
Appl Clin Genet. 2021; 14:353-361.
PMID: 34413666
PMC: 8369226.
DOI: 10.2147/TACG.S269622.
Pathogenesis, Diagnosis, and Clinical Implications of Hereditary Hemochromatosis-The Cardiological Point of View.
Danilowicz-Szymanowicz L, Swiatczak M, Sikorska K, Starzynski R, Raczak A, Lipinski P
Diagnostics (Basel). 2021; 11(7).
PMID: 34359361
PMC: 8304945.
DOI: 10.3390/diagnostics11071279.
Ethnic Differences in Iron Status.
Kang W, Barad A, Clark A, Wang Y, Lin X, Gu Z
Adv Nutr. 2021; 12(5):1838-1853.
PMID: 34009254
PMC: 8483971.
DOI: 10.1093/advances/nmab035.
Downregulation of FPN1 acts as a prognostic biomarker associated with immune infiltration in lung cancer.
Liu B, Song Z, Fan Y, Zhang G, Cao P, Li D
Aging (Albany NY). 2021; 13(6):8737-8761.
PMID: 33714956
PMC: 8034901.
DOI: 10.18632/aging.202685.
A disease-causing mutation K240E disrupts ferroportin trafficking by SUMO (ferroportin SUMOylation).
Bayele H, Srai S
Biochem Biophys Rep. 2021; 25:100873.
PMID: 33490642
PMC: 7809393.
DOI: 10.1016/j.bbrep.2020.100873.
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders.
Xu Y, Alfaro-Magallanes V, Babitt J
Br J Haematol. 2020; 193(5):882-893.
PMID: 33316086
PMC: 8164969.
DOI: 10.1111/bjh.17252.
Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk.
Ganz T, Aronoff G, Gaillard C, Goodnough L, Macdougall I, Mayer G
Kidney Med. 2020; 2(3):341-353.
PMID: 32734254
PMC: 7380433.
DOI: 10.1016/j.xkme.2020.01.006.
Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.
Viveiros A, Panzer M, Baumgartner N, Schaefer B, Finkenstedt A, Henninger B
Liver Int. 2020; 40(8):1941-1951.
PMID: 32450003
PMC: 7496278.
DOI: 10.1111/liv.14539.
Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features.
Vlasveld L, Janssen R, Bardou-Jacquet E, Venselaar H, Hamdi-Roze H, Drakesmith H
Pharmaceuticals (Basel). 2019; 12(3).
PMID: 31505869
PMC: 6789780.
DOI: 10.3390/ph12030132.